New triple cream takes on melasma in Head-to-Head trial
NCT ID NCT07508098
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 4 trial tested whether a triple-combination cream (containing N-acetylcysteine, hydroquinone, and triamcinolone acetate) works better than standard 4% hydroquinone cream for facial melasma. Fifty middle-aged men and women applied one of the creams twice daily for 8 weeks. The main goal was to see how many achieved at least a 60% reduction in their melasma severity score.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Triple combination cream (4.7% N-acetylcysteine, 2% hydroquinone, 0.1% triamcinolone acetate) and 4% hydroquinone cream
What this could lead to
If the triple cream works better, it could offer a more effective topical option for managing melasma with fewer side effects.
What could go wrong
This is a small, single-site study with only 50 participants, so results may not apply to everyone. Melasma often requires ongoing treatment, and any improvement may not be permanent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELASMA (FACIAL MELASMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatology Department of Tertiary Care Hospital
Rawalpindi, Punjab Province, 46000, Pakistan